Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Accumulated Expenses (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Accumulated Expenses data on record, last reported at $5.3 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 6.41% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $5.3 million, up 6.41%, while the annual FY2025 figure was $5.3 million, 6.41% up from the prior year.
  • Accumulated Expenses reached $5.3 million in Q4 2025 per ACRS's latest filing, up from $3.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $19.4 million in Q4 2023 and bottomed at $502000.0 in Q3 2024.
  • Average Accumulated Expenses over 5 years is $6.0 million, with a median of $5.5 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: plummeted 89.9% in 2024, then skyrocketed 648.21% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $10.1 million in 2021, then decreased by 13.43% to $8.7 million in 2022, then soared by 123.49% to $19.4 million in 2023, then crashed by 74.4% to $5.0 million in 2024, then rose by 6.41% to $5.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $5.3 million in Q4 2025, $3.8 million in Q3 2025, and $2.7 million in Q2 2025.